Genetic Basis of Chronic Hepatitis C Virus and Autoimmune Hepatitis: A Comparative Study

Shalaa Ay, Hafkoush RA, Ahmed MA, ElKhouly EH and Morsi MG*

1Medical Microbiology & Immunology, Alexandria Faculty of Medicine, Egypt
2Clinical Pathology (Hematology), Alexandria Faculty of Medicine, Egypt
3Tropical Department, Alexandria Faculty of Medicine, Egypt

Abstract

Background: It is now well established that HCV is of global importance affecting all countries, leading to a major global health problem that requires widespread active interventions for its prevention and control. Chronic hepatitis C was linked to the development of cirrhosis and Hepatocellular Carcinoma (HCC) in many areas of the world. WHO reported that Egypt has the highest prevalence (22%) in the world.

Objectives: Susceptibility to infection has been related to immunological disturbances. HCV and autoimmune hepatitis have been associated with HLA-A1, A6, A8-DRB01*15 alleles.

Methods: HLA alleles were detected by Sequence Specific Oligonucleotide Probe (SSOP) based on reverse hybridization after amplification of target HLA allele sequence by Real Time Polymerase Chain Reaction (RT-PCR). The non-organ-specific Antibodies Include Antinuclear (ANA), Smooth Muscle (ASMA), Anti-Mitochondrial Antibody (AMA), Perinuclear Antineutrophil Cytoplasmic (pANCA), Liver-Kidney Microsomal Antibodies (LKM-1) and Anticardiolipin Antibodies (ACA) were all measured by commercial Indirect Immunofluorescence (IF).

Conclusion: Current understanding of genetic basis (HLA alleles) of chronic HCV genotype 4 cases and autoimmune hepatitis cases free from HCV will aid a lot in treating both types of hepatitis using successful line of therapy as early as possible to save money and side effects of wrong medications.

Keywords: HCV genotype 4; HCV viral load; RT-PCR; INNO-LiPA; autoantibodies; IF HLA alleles; SSOP

Introduction

Hepatitis C virus is a hepatotropic and lymphotropic virus that has been found to be associated with various diseases and syndromes. Infection with HCV tends to become chronic in most infected individuals, reflecting an inability of the immune system to mount an effective antiviral response [1]. Autoimmune hepatitis is associated with chronic HCV infection [2]. Autoimmune hepatitis is a chronic disease of unknown cause, characterized by continuing hepatocellular inflammation and necrosis and tending to progress to cirrhosis. Immune serum markers frequently are present, autoantibodies against liver-specific and non-liver-specific antigens and increased immunoglobulin G (IgG) levels [3].

In August 2012, the Centers for Disease Control and Prevention (CDC) expanded their existing, risk-based testing guidelines to recommend a 1-time blood test for Hepatitis C Virus (HCV) infection in baby boomers—the generation born between 1945 and 1965, who account for approximately three fourths of all chronic HCV infections in the United States—without prior ascertainment of HCV risk.

The proposed pathogenesis of autoimmune hepatitis involves the combination of genetic predisposition and environmental triggers. The genetic predisposition may relate to several defects in immunologic control of autoreactivity. An environmental agent triggers the autoimmune response against liver antigens, causing necroinflammatory liver damage, fibrosis, and, eventually, cirrhosis, if left untreated [4].

Genetic susceptibility to developing autoimmune hepatitis has been associated with the HLA haplotypes B8, B14, DR3, DR4, and Dw4. CAA gene deletions are associated with the development of autoimmune hepatitis in younger patients [5]. HLA-DR3-positive patients are more likely than other patients to have aggressive disease, which is less responsive to medical therapy and more often results in liver transplantation; in addition, these patients are younger than other patients at the time of their initial presentation. HLA-DR4–positive patients are more likely to develop extrahepatic manifestations of their disease [6]. Among the several viruses implicated as triggering agents are rubella, Epstein-Barr, and hepatitis A, B, and C. Some authors have shown a high amino acid sequence homology between hepatitis C virus (HCV) polymerase and CYP2D6, the molecular target of Liver-Kidney Microsomal type 1 (LKM-1) antibody, which suggests that molecular mimicry, may trigger production of LKM-1 antibody in HCV infection [7]. Current evidence suggests that liver injury in a patient with autoimmune hepatitis is the result of a cell-mediated immunologic attack. Aberrant display of Human Leukocyte Antigen (HLA) class II on the surface of hepatocytes facilitates the exposure of normal liver cell...
membrane constituents to Antigen-Presenting Cells (APCs) [8]. The reasons for the aberrant HLA expression are unclear. It may be initiated or triggered by genetic factors, viral infections (e.g., acute hepatitis A or B, Epstein-Barr virus infection), and chemical agents (e.g., interferon, melatonin, alpha methyl dopa, oxygenisatin, nitrofurantoin, tienilic acid) [9]. As the etiology of autoimmune hepatitis is unknown. Several factors (e.g., viral infection, drugs, environmental agents, genetic factors) may trigger an autoimmune response and autoimmune disease. So, the current study will illustrate some genetic (HLA alleles) associated with clinical course and outcome of HCV and autoimmune hepatitis aiming at successful therapy of both conditions.

Subjects and Methods

Eighty adult patients with abnormal liver function tests (40 chronic HCV and 40 autoimmune hepatitis free of HBV and HCV) were enrolled in the current study selected from Tropical department of Alexandria Main University Hospital and Alexandria Armed Forces Hospital as well as 20 age and sex matched healthy controls. Exclusion criteria were cardiac, renal, diabetic, hypertensive and HIV positive cases. Their ages ranged (16-64 years) with a mean of (38 ± 12.5 years). Twenty unrelated healthy controls chosen from health care workers were included in the current study. All subjects (cases and controls; 100 in number) were 36 males (36%) and 64 females (64%). An informed consent was taken from all enrollees before sampling. Investigations done to all enrollees were; full history taking, clinical examination and the following laboratory tests [10-12] i. Complete blood picture using an automated cell counter (sysmex (KX-21 N), Roche, Japan), ii. Liver function tests (ALT, AST, bilirubin, albumin, alkaline phosphatase and gamma glutamyl transferase using Dimension RxL (Dad Behring Germany). iii. Autoantibody tests (ANA, ASMA, and AMA) and on human neutrophil substrate sections for (ANA, ASMA, AMA) and on human neutrophil substrate for p-ANCA to allow binding of antibodies to substrate. Any antibody not bound was removed by rinsing the slide. Bound antibodies of IgG class were detected by incubation of substrate with fluorescein with substrate labelled-antihuman IgG conjugate. The reactions were observed under fluorescent microscopy and presence of autoantibodies was demonstrated by an apple green fluorescence of specific structure in sera of patients. The titer was determined by testing serial dilutions and <20 was reported as a negative result. 6-HLA class II (DRB1*01*-DRB1*15) typing: genomic DNA was extracted from whole blood (after lysis by lysing buffer) using Qiagen spin column QIA amp DNA Blood Mini Kit. HLA classII alleles were determined at the genotype level with 2digit intermediate/low resolution. This was performed using INNO-LiPA plus; a line probe assay designed for molecular typing of HLA alleles at the allele group level. The principle of the test was based on the reverse hybridization of the amplified biotinylated DNA sample which was chemically denatured, and the separated strands were hybridized with specific oligonucleotide probes immobilized as parallel lines on membrane-based strips. This was followed by a stringent wash step to remove any mismatched amplified material. After the stringent wash, streptavidin conjugate with alkaline phosphatase was added and bound to any biotinylated hybrid previously formed. Incubation with a substrate solution containing a chromogen resulted in a purple/brown precipitate. The reaction was stopped by a wash step, and the reactivity pattern of the probe was recorded. An amplification kit (INNO-LiPA HLA A*1-8 and DRB1*15 amp Plus) was provided for standardized preparation of biotinylated amplified samples. The amplification kit was based on polymerase chain reaction (PCR). Amplification products were subsequently hybridized using 1 typing strip on which 37 sequence-specific DNA probes and 2 control probes were fixed. The INNO-LiPA HLA plus was designed to give the best possible resolution, at the allele group (this means the first 2 digits after the asterisk in an allele name when following standard HLA nomenclature e.g. HLA-DRB1*01).

Data Analysis

Descriptive statistics included range, mean ± SD, median, frequencies (number of cases) and percentages when appropriate. Comparisons of numerical variables between the study groups were made using the Mann Whitney U test for independent samples. To compare categorical data, the Chi squared (χ²) test was used. When the expected frequency was less than 5, Fisher Exact test was used instead. Accuracy was represented using the terms sensitivity and specificity. Receiver operator characteristic analysis was used to determine the optimum cut off value for the studied tests. Various variables were tested for correlation using the Spearman rank correlation coefficient equation for non-normal variables (r). P values less than 0.05 were considered statistically significant. Normality of data was checked by the Kolmogorov Smirnov test. Our methods violated the normal assumption; therefore, the data were analyzed using non-parametric tests. Two-tailed tests were used where appropriate. All statistical calculations were performed using the computer programs Microsoft Excel 2007 (Microsoft Corporation, NY, and United States) and SPSS (Statistical Package for the Social Sciences; SPSS Inc., USA) version 15 for Microsoft Windows.

Results

In Table 1, comparing the different groups according to HCV RNA levels.

### Table 1: HCV RNA levels among Chronic HCV cases group I.

<table>
<thead>
<tr>
<th>HCV viral load (IU/ml)</th>
<th>Chronic HCV (n=20)</th>
<th>Cirrhotics (n=20)</th>
<th>Test of sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HCV RNA×10^4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min.—Max.</td>
<td>2.14–160.0</td>
<td>16.31–1528.10</td>
<td><strong>&lt;0.008</strong></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>51.01 ± 47.85</td>
<td>251.72 ± 43.85</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>38.50</td>
<td>83.36</td>
<td></td>
</tr>
<tr>
<td><strong>p1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>p2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **p**: p value for comparing between the different studied groups |
| **p1**: p value for comparing between control with each other group |
| **p2**: p value for comparing between Ch. Hepatitis with each other group |

KW: for Kruskal Wallis test
MW: for Mann Whitney test

*: Statistically significant at p ≤ 0.05

### Table 2: HCV viral load among chronic HCV cases (group I).

<table>
<thead>
<tr>
<th>HCV viral load (IU/ml)</th>
<th>Chronic HCV (n=20)</th>
<th>Cirrhotics (n=20)</th>
<th>Total (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very low (&lt;10^4)</strong></td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Low (10^4-10^5)</td>
<td>0.00</td>
<td>0.00</td>
<td>8.00</td>
</tr>
<tr>
<td>Moderate (10^5-10^6)</td>
<td>12.00</td>
<td>12.00</td>
<td>36.00</td>
</tr>
<tr>
<td>High (10^6-10^7)</td>
<td>2.00</td>
<td>30.00</td>
<td>14.23</td>
</tr>
<tr>
<td><strong>Very high (&gt;10^7)</strong></td>
<td>0.00</td>
<td>2.00</td>
<td>3.30</td>
</tr>
</tbody>
</table>

J Medical Microbiol Diagnosis
Bacteriologist Pathogenecity & Epidemiology
ISSN: 2161-0703 JMMD, an open access journal
Anti-liver kidney microsomal antibody. 
AMA: Anti-mitochondrial antibody. 
ANA: Anti-nuclear antibodies.

Discussion
Autoimmune hepatitis (AIH) is an unresolved hepatocellular inflammation of unknown cause that is characterized by presence of periportal hepatitis on histologic examination, tissue antibodies in serum and hypergammaglobulinemia [13]. In the current study the sensitivity of ANA, ASMA, AMA, AL/KM, p-ANCA and ACA was 48.6%, 51.4%, 2.7%, 8.1%, 56.8% and 18.9% respectively with high specificity (100% for all antibodies except for ANA 95.7%, ASMA 87% and ACA 75.4%). However, using a complete profile of autoantibodies increased the overall sensitivity to 100% and specificity to 91.4%. These findings were in agreement with [14]. They postulated that simultaneous presence of more than one antibody increased the probability of AIH diagnosis [14]. Other investigators reported high specificity (100%) and 81% sensitivity among their AIH cases [15]. Furthermore, other researchers found that these autoantibodies could be used as useful prognostic markers [16].

The mechanism of autoimmunity is not fully understood but may involve binding of antigenic peptides to human leukocyte antigen (HLA) [17]. Several researchers have tried to establish a relationship between HLA class I & II and chronic hepatitis either by HCV or autoimmune mechanism however, the results were inconsistent. With the development of polymerase chain reaction (PCR), the identification of HLA alleles at the DNA level had allowed more precise determination of susceptible epitopes showing a strong association with various viral and autoimmune hepatitis [18].

The sensitivity of ANA, ASMA, AMA, AL/KM, p-ANCA and ACA was 48.6%, 51.4%, 2.7%, 8.1%, 56.8% and 18.9% respectively with high specificity (100% for all antibodies except for ANA 95.7%, ASMA 87% and ACA 75.4%). However, using a complete profile of autoantibodies increased the overall sensitivity to 100% and specificity to 91.4%. These findings were in agreement with [14]. They postulated that simultaneous presence of more than one antibody increased the probability of AIH diagnosis [14]. Other investigators reported high specificity (100%) and 81% sensitivity among their AIH cases [15]. Furthermore, other researchers found that these autoantibodies could be used as useful prognostic markers [16].

The mechanism of autoimmunity is not fully understood but may involve binding of antigenic peptides to human leukocyte antigen (HLA) [17]. Several researchers have tried to establish a relationship between HLA class I & II and chronic hepatitis either by HCV or autoimmune mechanism however, the results were inconsistent. With the development of polymerase chain reaction (PCR), the identification of HLA alleles at the DNA level had allowed more precise determination of susceptible epitopes showing a strong association with various viral and autoimmune hepatitis [18].

In the present study HLA A1, DBR1*07, DBR1*11 were highly associated with chronic HCV cases (p<0.003*, 0.004*, 0.005 respectively compared to controls. While DBR1*03, DBR1*04 controls were not infected with HCV, denoting that these may be protective alleles against HCV infection. These findings were in accordance with others done elsewhere who claimed that DBR1*07 is the allele associated with persistence of HCV and non response to Interferon, while HLADR*11 was associated with self limiting and spontaneous clearance of the virus [2,19-22]. Among our autoimmune hepatitis cases HLA A6, A8 and DBR1*03 and DBR1*05 were the predominant alleles (p<0.002*, 0.003*, 0.005*, 0.0034*) respectively. Researches done all over the world reported similar findings [3,6,19].

We can conclude that certain HLA alleles of class I or and II could be associated with both hepatitis (either caused by HCV or autoimmune) and can predict clinical course and outcome of the disease. Also, our findings could help clinicians in selecting proper regimen as early as possible saving money and complications of wrong medications.

Acknowledgment
We would like to acknowledge Alexandria Main Armed Forces Hospital and Alexandria Faculty of Medicine, Egypt who sponsored materials and equipment used in our current study.

References


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
• User friendly/feasible website-translation of your paper to 50 world's leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:
• 200 Open Access Journals
• 15,000 editorial team
• 24/7 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (portial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission